Spotify Apple Youtube

Category: FIB-4

All Podcast Categories
S4-34 - Drug Development Stories from EASL and ADA: Part 2

S4-34 – Drug Development Stories from EASL and ADA: Part 2

Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. The session explores a range of topics around the subject of drug development, including notes on orals versus injectables, diabetes medications with potential in the NASH space, new clinical trial data, different drug classes and much more.

July 26, 2023
S4-33.4 - More Presentation Insights on Frequency of Testing, NITs and Biopsy

S4-33.4 – More Presentation Insights on Frequency of Testing, NITs and Biopsy

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. This final session focuses on another paper by Vincent Wong which sparks discussion around the plausibility of shifting from biopsy to NITs and the cost effectiveness and frequency of testing.

July 23, 2023
S4-33.3 - Steatotic Liver Disease, HCC and Mechanisms of Fibrosis Resolution

S4-33.3 – Steatotic Liver Disease, HCC and Mechanisms of Fibrosis Resolution

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. This session focuses on a study aimed at connecting steatotic liver disease in patients without cirrhosis to HCC outcomes over a ten year period. After, the group unpacks how little is known about the mechanisms of fibrosis resolution.

July 22, 2023
S4-33.2 - Unmet Needs in the Primary Care Setting for Disease Identification

S4-33.2 – Unmet Needs in the Primary Care Setting for Disease Identification

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the presentations of interest from EASL Congress 2023. In this conversation, Ian points to a presentation on automated FIB-4 score calculation and e-reminders to detect advanced liver disease in patients with type 2 diabetes. The group goes on to explore big picture questions on the topic of disease identification and tease the differences between hepatology and private practices and management of a population-level disease.

July 22, 2023
S4-33.1 - EASL Congress 2023: Focus on New Nomenclature

S4-33.1 – EASL Congress 2023: Focus on New Nomenclature

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the new NAFLD/NASH nomenclature shared at EASL Congress 2023. The groups outlines what the changes entail and shares practical considerations around how to implement the changes in different settings and with patients.

July 22, 2023
S4-33 - EASL Congress: Nomenclature and More Compelling Presentations

S4-33 – EASL Congress: Nomenclature and More Compelling Presentations

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. The session focuses on new nomenclature and emerging stories around patient identification, NITs, fibrosis resolution and more.

July 19, 2023
S4-32.4 - The Potential of NASH Drugs as Adjuvant Therapy

S4-32.4 – The Potential of NASH Drugs as Adjuvant Therapy

Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. This final conversation considers important topics yet to be addressed in the preceding sessions. One of the prevailing themes explored is the potential of NASH drugs as adjuvant therapy.

July 16, 2023
S2-5 - Key Insights from the American Diabetes Association 83rd Scientific Sessions

S2-5 – Key Insights from the American Diabetes Association 83rd Scientific Sessions

Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.

July 13, 2023
S4-32 - Drug Development Stories from EASL and ADA: Part 1

S4-32 – Drug Development Stories from EASL and ADA: Part 1

Stephen Harrison and Jörn Schattenberg join Roger Green to discuss newly released Phase 3 MAESTRO-NASH data on resmetirom and the wider NASH therapeutic landscape, AI-assisted digital pathology, what the field understands about liver volume reduction, an increasing burden of cirrhosis and much more. This episode is packed with robust analysis and insights stemming from a busy past month at the EASL Congress and ADA Scientific Sessions meetings.

July 12, 2023
S4-31.4 - EASL Congress and ADA Scientific Sessions: Reshaping the way we think about Fatty Liver Disease

S4-31.4 – EASL Congress and ADA Scientific Sessions: Reshaping the way we think about Fatty Liver Disease

Roger Green is joined by Jörn Schattenberg to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This final conversation explores a range of topics including the role of artificial intelligence and general observations around how the different questions being asked in 2023 versus 2019 demonstrate dramatic changes in how the field understands Fatty Liver disease.

July 9, 2023
Stay In Touch
Apple Spotify Youtube

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.

Learn More